| Literature DB >> 25385620 |
Kazuo Takayama1, Yuta Morisaki2, Shuichi Kuno2, Yasuhito Nagamoto3, Kazuo Harada4, Norihisa Furukawa2, Manami Ohtaka5, Ken Nishimura6, Kazuo Imagawa7, Fuminori Sakurai8, Masashi Tachibana2, Ryo Sumazaki9, Emiko Noguchi10, Mahito Nakanishi5, Kazumasa Hirata4, Kenji Kawabata11, Hiroyuki Mizuguchi12.
Abstract
Interindividual differences in hepatic metabolism, which are mainly due to genetic polymorphism in its gene, have a large influence on individual drug efficacy and adverse reaction. Hepatocyte-like cells (HLCs) differentiated from human induced pluripotent stem (iPS) cells have the potential to predict interindividual differences in drug metabolism capacity and drug response. However, it remains uncertain whether human iPSC-derived HLCs can reproduce the interindividual difference in hepatic metabolism and drug response. We found that cytochrome P450 (CYP) metabolism capacity and drug responsiveness of the primary human hepatocytes (PHH)-iPS-HLCs were highly correlated with those of PHHs, suggesting that the PHH-iPS-HLCs retained donor-specific CYP metabolism capacity and drug responsiveness. We also demonstrated that the interindividual differences, which are due to the diversity of individual SNPs in the CYP gene, could also be reproduced in PHH-iPS-HLCs. We succeeded in establishing, to our knowledge, the first PHH-iPS-HLC panel that reflects the interindividual differences of hepatic drug-metabolizing capacity and drug responsiveness.Entities:
Keywords: CYP2D6; SNP; hepatocyte; human iPS cells; personalized drug therapy
Mesh:
Substances:
Year: 2014 PMID: 25385620 PMCID: PMC4250156 DOI: 10.1073/pnas.1413481111
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205